EDIT Editas Medicine, Inc. Stock Quote

EDIT [NASD]

Index	-	P/E	-	EPS (ttm)	-2.73	Insider Own	0.50%	Shs Outstand	68.48M	Perf Week	0.27%
Market Cap	696.36M	Forward P/E	-	EPS next Y	-3.52	Insider Trans	-6.94%	Shs Float	68.45M	Perf Month	-33.17%
Income	-186.30M	PEG	-	EPS next Q	-0.82	Inst Own	64.60%	Short Float	18.43%	Perf Quarter	-29.45%
Sales	25.80M	P/S	26.99	EPS this Y	-43.90%	Inst Trans	-13.26%	Short Ratio	7.34	Perf Half Y	-70.61%
Book/sh	7.49	P/B	1.49	EPS next Y	-8.80%	ROA	-26.90%	Target Price	32.38	Perf Year	-66.35%
Cash/sh	7.81	P/C	1.43	EPS next 5Y	-	ROE	-32.90%	52W Range	9.71 - 73.03	Perf YTD	-58.04%
Dividend	-	P/FCF	-	EPS past 5Y	1.20%	ROI	-34.90%	52W High	-84.74%	Beta	2.09
Dividend %	-	Quick Ratio	13.60	Sales past 5Y	33.40%	Gross Margin	-	52W Low	14.73%	ATR	1.37
Employees	264	Current Ratio	13.60	Sales Q/Q	4.60%	Oper. Margin	-	RSI (14)	37.31	Volatility	12.46% 10.11%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	14.20%	Profit Margin	-	Rel Volume	0.60	Prev Close	11.87
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 04 BMO	Payout	-	Avg Volume	1.72M	Price	11.14
Recom	2.60	SMA20	-18.41%	SMA50	-31.17%	SMA200	-65.35%	Volume	1,040,738	Change	-6.15%

Oct-19-21

Initiated

SVB Leerink

Mkt Perform

$41

Sep-24-21

Initiated

Stifel

Hold

$65

Sep-10-21

Upgrade

Oppenheimer

Perform → Outperform

$42 → $80

Aug-09-21

Upgrade

Truist

Hold → Buy

$45 → $80

Aug-05-21

Upgrade

Evercore ISI

Underperform → Outperform

$20 → $60

Jun-04-21

Resumed

Robert W. Baird

Outperform

$44

May-04-21

Initiated

RBC Capital Mkts

Sector Perform

$40

Apr-16-21

Initiated

Goldman

Sell

$20

Mar-22-21

Initiated

Credit Suisse

Outperform

$58

Mar-01-21

Downgrade

Barclays

Overweight → Equal Weight

$46

Feb-26-21

Downgrade

Truist

Buy → Hold

$45

Jan-19-21

Downgrade

Morgan Stanley

Equal-Weight → Underweight

$64 → $45

Jan-07-21

Downgrade

Raymond James

Outperform → Mkt Perform

Dec-10-20

Upgrade

Wells Fargo

Equal Weight → Overweight

$69

Nov-03-20

Initiated

Robert W. Baird

Underperform

$14

Jun-18-20

Resumed

SunTrust

Buy

$45

Feb-21-20

Initiated

Wells Fargo

Equal Weight

$28

Apr-12-19

Initiated

Evercore ISI

Outperform

Oct-10-18

Initiated

Guggenheim

Neutral

Sep-21-18

Initiated

Raymond James

Outperform

$40

May-13-22 11:52AM	Why Editas Medicine's Shares Fell 28.9% This Week Motley Fool +9.81%
10:30AM	Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia Zacks
May-12-22 04:30PM	Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia GlobeNewswire +7.78%
May-10-22 06:50AM	Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth? Simply Wall St.
May-04-22 01:30PM	Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference GlobeNewswire +11.50%
11:54AM	Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates Zacks
07:55AM	Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates Zacks
06:45AM	Editas Medicine Announces First Quarter 2022 Results and Business Updates GlobeNewswire
May-02-22 04:31PM	Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting GlobeNewswire +7.78%
Apr-27-22 03:03PM	Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
06:55AM	Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update GlobeNewswire
Apr-26-22 09:00AM	Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia GlobeNewswire -6.87%
Apr-19-22 06:20AM	3 Ominous Reasons to Avoid This Biotech Pioneer Motley Fool
Apr-15-22 09:41AM	Jim Cramer Says You Should Sell These 10 Stocks Insider Monkey
Apr-14-22 02:11PM	Former Sarepta, Biogen exec joins Editas as CEO American City Business Journals -11.19%
07:30AM	Editas Medicine Appoints Gilmore ONeill as Chief Executive Officer GlobeNewswire
Apr-12-22 11:47AM	Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study Zacks
Apr-11-22 09:00AM	Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10 GlobeNewswire
Apr-08-22 01:00PM	Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-21-22 07:44AM	Editas (EDIT) Soars 6.3%: Is Further Upside Left in the Stock? Zacks -5.17%
Mar-01-22 04:36PM	Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test Investor's Business Daily
11:26AM	Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents Benzinga
08:55AM	Patent Ruling Is a Setback for Gene-Editing Firms Tied to Crispr Nobelists Barrons.com
Feb-28-22 08:15PM	University of California loses breakthrough CRISPR patent in PTO ruling American City Business Journals
04:01PM	Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference GlobeNewswire
04:15AM	Editas Medicine (NASDAQ:EDIT) adds US$129m to market cap in the past 7 days, though investors from a year ago are still down 61% Simply Wall St.
Feb-25-22 11:51AM	Editas' (EDIT) Q4 Loss Narrows, Revenues Trump Estimates Zacks +6.56%
Feb-24-22 07:45AM	Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates Zacks +10.06%
06:30AM	Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates GlobeNewswire
Feb-23-22 11:44AM	Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More Zacks
09:54AM	10 Genomics Stocks in Cathie Woods Portfolio That Are Underperforming Insider Monkey
Feb-17-22 05:45PM	Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates Zacks -6.19%
03:03PM	Will Editas Medicine (EDIT) Report Negative Earnings Next Week? What You Should Know Zacks
Feb-16-22 06:15AM	Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update GlobeNewswire
Feb-11-22 12:02PM	Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates Zacks -6.71%
Feb-08-22 02:15PM	Editas quietly fires chief medical officer American City Business Journals -9.73%
12:40PM	Editas Suddenly Terminates Chief Medical Officer Without An Explanation Benzinga
Feb-07-22 01:05PM	Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3 Zacks
09:38AM	Orion Capital Management LLC Buys Qualcomm Inc, Distillate U.S. ... GuruFocus.com
Feb-02-22 06:40AM	2 Biotech Stocks That Could Skyrocket This Year Motley Fool -7.47%
Jan-26-22 05:38PM	Berger Financial Group, Inc Buys Hartford Core Bond ETF, Apple Inc, Independence Realty Trust ... GuruFocus.com
Jan-24-22 01:38PM	DDD Partners, LLC Buys Intel Corp, Novo Nordisk A/S, Broadcom Inc, Sells Adaptive ... GuruFocus.com
Jan-19-22 10:46AM	Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug Zacks
Jan-14-22 11:43AM	Here is What Hedge Funds Think About Editas Medicine, Inc. (EDIT) Insider Monkey
05:19AM	What Kind Of Investors Own Most Of Editas Medicine, Inc. (NASDAQ:EDIT)? Simply Wall St.
Jan-13-22 05:24PM	Why Editas Medicine Stock Is Tumbling This Week Motley Fool -6.94%
03:56PM	The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To These CRISPR Stocks Investor's Business Daily
Jan-11-22 02:46PM	The Gene-Editing Industry Weighs In on Outlook at J.P. Morgan Conference Barrons.com
Jan-10-22 07:00AM	Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference GlobeNewswire
Jan-04-22 06:58AM	Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-20-21 08:32AM	Dr. Jessica Hopfield Appointed to Berkeley Lights Board of Directors GlobeNewswire
07:00AM	Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia GlobeNewswire
Dec-17-21 10:06AM	uniQure (QURE) Falls on Data From Huntington's Disease Study Zacks +7.37%
09:04AM	10 Best Genomics Stocks to Buy Now Insider Monkey
Dec-16-21 10:00AM	Bristol Myers' (BMY) Orencia Gets FDA Nod for New Indication Zacks -7.05%
09:38AM	Apellis (APLS), Sobi Get EU Nod for Rare Blood Disorder Drug Zacks
Dec-15-21 11:16AM	Alnylam (ALNY) Files for Oxlumo Label Expansion in US & EU Zacks
Dec-14-21 11:06AM	Trevena (TRVN) to Begin Clinical Study on Pain Candidate Zacks
Dec-13-21 10:55AM	BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today InvestorPlace
Dec-12-21 06:00PM	Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting GlobeNewswire
Dec-10-21 10:21AM	Cytokinetics' (CYTK) Aficamten Gets Breakthrough Therapy Tag Zacks
Dec-09-21 11:38AM	Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status Zacks
Dec-08-21 05:57AM	3 Beaten-Down Biotech Stocks -- Are They Bargains Now? Motley Fool
Dec-07-21 10:00AM	Editas (EDIT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Zacks +10.33%
10:00AM	After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Editas (EDIT) Zacks
Dec-03-21 10:00AM	Here's Why Editas (EDIT) is Poised for a Turnaround After Losing 20.6% in 4 Weeks Zacks -7.69%
Nov-30-21 05:36AM	We Think Editas Medicine (NASDAQ:EDIT) Can Afford To Drive Business Growth Simply Wall St.
Nov-25-21 10:56AM	Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study Zacks
Nov-23-21 12:01PM	CRISPR's (CRSP) CAR-T Cell Therapy Gets FDA's RMAT Designation Zacks
11:52AM	Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST Zacks
Nov-22-21 11:23AM	BioMarin's (BMRN) Dwarfism Drug Gets FDA's Nod, Stock Up Zacks
Nov-17-21 03:01AM	These 40 Mass. companies made the new Deloitte Fast 500 list American City Business Journals
Nov-16-21 09:08AM	Coherus' (CHRS) Toripalimab Gets Orphan Drug Tag for Rare Cancer Zacks
Nov-12-21 07:00AM	Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting GlobeNewswire
Nov-09-21 11:00AM	Editas (EDIT) Q3 Earnings Beat Estimates, Revenues Fall Y/Y Zacks
Nov-08-21 04:00PM	Editas Medicine, Inc (EDIT) Q3 2021 Earnings Call Transcript Motley Fool +8.19%
12:52PM	Why Editas Medicine Stock Is Jumping Today Motley Fool
08:25AM	Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM	Editas Medicine Announces Third Quarter 2021 Results and Business Updates GlobeNewswire
Nov-05-21 10:09AM	Biotech Stocks' Q3 Earnings on Nov 8: VTRS, EDIT & More Zacks
Nov-04-21 09:02AM	Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition GlobeNewswire
Nov-02-21 05:50PM	Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know Zacks
10:02AM	Editas (EDIT) to Report Q3 Earnings: What's in the Cards? Zacks
Nov-01-21 03:01PM	Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for Zacks +5.15%
Oct-28-21 09:00AM	Editas Medicine Names Bernadette Connaughton to Board of Directors GlobeNewswire
06:27AM	Should You Scoop Up Shares of This Promising Biotech on the Dip? Motley Fool
Oct-26-21 09:34AM	Hedge Funds Are Selling Editas Medicine, Inc. (EDIT) Insider Monkey
Oct-25-21 04:01PM	Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update GlobeNewswire
Oct-20-21 09:00AM	Clinical Data from Editas Medicines Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress GlobeNewswire
Oct-18-21 06:45AM	2 Tricks and a Treat for Gene Therapy Investors Motley Fool
Oct-16-21 09:35AM	Insiders in Editas Medicine, Inc. (NASDAQ:EDIT) are down 18% on their US$1.4m purchase despite recent gains Simply Wall St.
Oct-15-21 07:47AM	The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics Zacks
Oct-14-21 09:40AM	4 Biotechs to Watch Amid Rising Prominence of Gene Therapies Zacks
Oct-13-21 10:08AM	Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease Zacks
Oct-07-21 08:00AM	Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting GlobeNewswire
07:18AM	3 Spooky Healthcare Stocks I Would Avoid in October Motley Fool
Sep-30-21 04:02PM	Editas Stock Firestorm Rages On; CRISPR Gene-Editing Stock Flashes Sell Signal Investor's Business Daily
10:37AM	Editas (EDIT) Down on Initial Data From Eye Disease Study Zacks
08:00AM	Editas Medicine to Present at Chardans 5th Annual Genetic Medicines Conference GlobeNewswire
Sep-29-21 04:15PM	Editas Medicine Stock Plunges As CRISPR Gene-Editing Drug Fails To Impress Investor's Business Daily -18.97%

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Eaton Bruce	EVP, CHIEF BUSINESS OFFICER	May 09	Sale	13.11	297	3,895	66,544	May 11 04:15 PM
Eaton Bruce	EVP, CHIEF BUSINESS OFFICER	Apr 01	Sale	19.64	1,258	24,707	66,841	Apr 04 04:30 PM
ROBERTSON MICHELLE	EVP, CHIEF FINANCIAL OFFICER	Mar 03	Sale	17.33	767	13,290	84,194	Mar 07 04:15 PM
Eaton Bruce	EVP, CHIEF BUSINESS OFFICER	Mar 03	Sale	17.33	403	6,983	68,386	Mar 07 04:15 PM
Eaton Bruce	EVP, CHIEF BUSINESS OFFICER	Feb 08	Sale	17.63	302	5,323	31,196	Feb 10 04:36 PM
ROBERTSON MICHELLE	Chief Financial Officer	Jan 11	Sale	25.70	1,744	44,821	31,462	Jan 13 04:17 PM
MULLEN JAMES C	CEO	Jan 03	Sale	26.95	18,252	491,979	75,898	Jan 04 04:23 PM
Michaels Lisa Anne	EVP/Chief Medical Officer	Nov 12	Sale	38.33	1,568	60,101	18,432	Nov 15 04:26 PM
Eaton Bruce	EVP, Chief Business Officer	Nov 09	Sale	40.61	287	11,655	28,026	Nov 10 06:52 PM
MULLEN JAMES C	CEO	Oct 18	Sale	38.03	13,805	525,033	57,673	Oct 20 04:16 PM
ROBERTSON MICHELLE	Chief Financial Officer	Aug 09	Option Exercise	30.65	2,500	76,625	31,235	Aug 10 04:33 PM
Eaton Bruce	EVP, CHIEF BUSINESS OFFICER	Aug 09	Sale	57.17	287	16,408	68,099	Apr 04 04:30 PM
ROBERTSON MICHELLE	Chief Financial Officer	Aug 09	Sale	60.00	2,500	150,000	28,735	Aug 10 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience